Agree with your comment @Melody432 but the overall situation seems like a possible catch-22.
On one hand they have a product that appears to have multiple applications and therefore warrants multiple concurrent workstreams to explore the different applications. Given the lag time getting from idea > research > POC > testing > approval (and all the steps I've probably missed) I imagine it's only logical that a Company explore multiple applications concurrently.
On the other hand, I can understand why an investor might want AVH to focus on their core business and get it somewhere towards cashflow positivity? I suppose the team is big enough to handle the different workloads, but part of me would want them to absolutely nail the primary application before incurring all the time/costs/workload for the others.
Would be interested on your views on this, if you care to share.
Cheers
- Forums
- ASX - By Stock
- AVH
- Ann: AVITA Medical Establishes Proof of Concept for Gene Therapy
Ann: AVITA Medical Establishes Proof of Concept for Gene Therapy, page-13
-
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVH (ASX) to my watchlist
|
|||||
Last
$2.80 |
Change
0.120(4.48%) |
Mkt cap ! $193.9M |
Open | High | Low | Value | Volume |
$2.78 | $2.86 | $2.77 | $457.2K | 163.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 4531 | $2.80 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.83 | 2500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 4531 | 2.800 |
2 | 5678 | 2.790 |
1 | 17 | 2.770 |
1 | 10000 | 2.750 |
1 | 3308 | 2.720 |
Price($) | Vol. | No. |
---|---|---|
2.830 | 2500 | 1 |
2.840 | 17 | 1 |
2.850 | 1150 | 1 |
2.860 | 2800 | 2 |
2.870 | 4250 | 2 |
Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
Featured News
AVH (ASX) Chart |